The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
碩士 === 長庚大學 === 企業管理研究所 === 96 === The emergency needs of adopting external supports from other resources of biotechnology industry are noticed especially while companies acquiring break-through in product development research, clinical trials, product commercialization, marketing, and tackling prob...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Published: |
2008
|
Online Access: | http://ndltd.ncl.edu.tw/handle/77208370580070317324 |
id |
ndltd-TW-096CGU05121022 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-096CGU051210222016-05-13T04:15:00Z http://ndltd.ncl.edu.tw/handle/77208370580070317324 The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan 國內生技醫藥產業策略聯盟之優先因素評估 Yi Ru Chen 陳怡如 碩士 長庚大學 企業管理研究所 96 The emergency needs of adopting external supports from other resources of biotechnology industry are noticed especially while companies acquiring break-through in product development research, clinical trials, product commercialization, marketing, and tackling problems in strategic management. The number of strategic alliance was increasing, which demonstrated the fast developing status of biotech industry in Taiwan. However, the motivations of initiating strategic alliance with external resources were found varied from different stages and types of biotech companies. Some may want to adopt scarce resources or share cost and risk of development; others may seek complementary resources or gain market competitive advantages. Therefore, the study of determinants and prioritization related to decision making of strategic alliance among particular parts of biotech companies are warranted for industrial successfulness. This study has followed steps from factors construction to application of analytic hierarchy process for the research protocol. Biotech companies in the categories of genetic engineering protein drugs, allergic pharmaceutics, human blood substitutes, and vaccine products were selected as study subjects. Twenty criteria/questions in four constructs, such as criteria for alliances, industrial characteristics, technologies and products, and needs of external supports, were constructed from literature review and experts validation in the measurement. The priority for determining strategic alliance was concluded accordingly as: 1) Technology Platform or equipment. 2) Improve product competitive ability. 3) technical knowledge and ability compatible or complementary. 4) Complementarity of capabilities. 5) Professional employee in a specialized field. Finally, this study provides valuable information for this industry to choose their appropriate partners for future developments. K. H. Hsu 許光宏 2008 學位論文 ; thesis 131 |
collection |
NDLTD |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 長庚大學 === 企業管理研究所 === 96 === The emergency needs of adopting external supports from other resources of biotechnology industry are noticed especially while companies acquiring break-through in product development research, clinical trials, product commercialization, marketing, and tackling problems in strategic management. The number of strategic alliance was increasing, which demonstrated the fast developing status of biotech industry in Taiwan.
However, the motivations of initiating strategic alliance with external resources were found varied from different stages and types of biotech companies. Some may want to adopt scarce resources or share cost and risk of development; others may seek complementary resources or gain market competitive advantages. Therefore, the study of determinants and prioritization related to decision making of strategic alliance among particular parts of biotech companies are warranted for industrial successfulness.
This study has followed steps from factors construction to application of analytic hierarchy process for the research protocol. Biotech companies in the categories of genetic engineering protein drugs, allergic pharmaceutics, human blood substitutes, and vaccine products were selected as study subjects. Twenty criteria/questions in four constructs, such as criteria for alliances, industrial characteristics, technologies and products, and needs of external supports, were constructed from literature review and experts validation in the measurement.
The priority for determining strategic alliance was concluded accordingly as: 1) Technology Platform or equipment. 2) Improve product competitive ability. 3) technical knowledge and ability compatible or complementary. 4) Complementarity of capabilities. 5) Professional employee in a specialized field.
Finally, this study provides valuable information for this industry to choose their appropriate partners for future developments.
|
author2 |
K. H. Hsu |
author_facet |
K. H. Hsu Yi Ru Chen 陳怡如 |
author |
Yi Ru Chen 陳怡如 |
spellingShingle |
Yi Ru Chen 陳怡如 The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan |
author_sort |
Yi Ru Chen |
title |
The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan |
title_short |
The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan |
title_full |
The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan |
title_fullStr |
The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan |
title_full_unstemmed |
The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan |
title_sort |
prioritization of strategic alliance among biopharmaceutical companies in taiwan |
publishDate |
2008 |
url |
http://ndltd.ncl.edu.tw/handle/77208370580070317324 |
work_keys_str_mv |
AT yiruchen theprioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan AT chényírú theprioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan AT yiruchen guónèishēngjìyīyàochǎnyècèlüèliánméngzhīyōuxiānyīnsùpínggū AT chényírú guónèishēngjìyīyàochǎnyècèlüèliánméngzhīyōuxiānyīnsùpínggū AT yiruchen prioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan AT chényírú prioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan |
_version_ |
1718266506172694528 |